Doctor Care Anywhere Group PLC Shs Chess Depository Interests Repr 1 sh
AASX:DOC0.11
AUD
0.00
(0.00%)
ISIN
AU0000116238
Return %
Stock
S&P 500
1Y
-24.14
14.39
3Y
92.98
81.42
5Y
-84.62
68.62
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Laura O’Riordan
- Full Time Employees
- 452
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 19-21 Great Portland Street London GL United Kingdom W1W 8QB
- IPO Date
- Dec 4, 2020
- Website
- doctorcareanywhere.com
- Similar Companies
- Business
- Doctor Care Anywhere Group PLC (ASX:DOC) provides telehealth services through its proprietary digital platform, delivering remote GP and advanced clinical practitioner appointments, mental health support, physiotherapy, comprehensive health assessments, specialist care pathways, and treatments for allergies, colds, flu, minor illnesses, gut health, joint and muscle conditions, men's and women's health, sexual health, skin conditions, and lifestyle support including weight management; the company also offers medical letters, imaging support, blood testing, prescriptions, patient records, referrals, and fit notes to individual patients, businesses, insurers, and healthcare providers. Founded in 2014 and headquartered at 19-21 Great Portland Street, Second Floor, Mayfair, London, W1W 8QB, United Kingdom, the company operates primarily in the United Kingdom and Republic of Ireland, with a listing on the Australian Securities Exchange. Doctor Care Anywhere Group PLC derives most revenue from virtual healthcare services, technology platform licensing, and digital design services, targeting corporate customers seeking proactive, data-driven employee wellbeing programs alongside private medical insurers and individual consumers. Recent developments include a headquarters relocation to Mayfair, London effective November 2025, completion of a transformation program with significant headcount reduction to improve margins as reported in Q1 2025 alongside a strategic partnership, an investor roadshow in Australia in September 2025 emphasizing revenue growth to £19.2 million (A$39.8 million) in 1H25 with 51% underlying contribution margin, expansion of digital care pathways such as AI mental health, musculoskeletal, dermatology, diagnostics, and health assessments, appointment of a new company secretary in November 2025, and a director's stake increase; the company pursues scaling services, new PMI and corporate deals, and material margin expansion toward 15% EBITDA within three to five years.